Genetic stability of Sabin 1 strain of poliovirus: Implications for quality control of oral poliovirus vaccine

Virology

Volumn 245, Issue 2, 1998, Pages 183-187

  Rezapkin, Gennady V ^a   Alexander, William ^a   Dragunsky, Eugenia ^a   Parker, Monica ^a   Pomeroy, Kitty ^a   Asher, David M ^a   Chumakov, Konstantin M ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; GENETIC STABILITY; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; STRAIN DIFFERENCE; VACCINE PRODUCTION;

ANIMALIA; POLIOVIRUS; RNA VIRUSES;

EID: 0032486469     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9191     Document Type: Article

References (23)

1. Benyesh-Melnick M., Melnick J. L. The use ofin vitro. Pan-American Health Organization, Sc. Pub. 1959;PAHO, Washington. p. 179-198.
2. Bouchard M. J., Lam D. H., Racaniello V. R. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J. Virol. 69:1995;4972-4978.
3. Christodoulou C., Colbere-Garapin F., Macadam A., Taffs L. F., Marsden S., Minor P., Horaud F. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J. Virol. 64:1990;4922-4929.
4. Chumakov K., Norwood L., Parker M., Dragunsky E., Taffs R., Ran Y., Ridge J., Levenbook I. Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulence. Dev. Biol. Standard. 78:1993;79-89.
5. Chumakov K. M. PCR engineering of viral quasispecies: A new method to preserve and manipulate genetic diversity of RNA virus populations. J. Virol. 70:1996;7331-7334.
6. Chumakov K. M., Powers L. B., Noonan K. E., Roninson I. B., Levenbook I. S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. USA. 88:1991;199-203.
7. Domingo E., Martinez-Salas E., Sobrino F., de la Torre J. C., Portela A., Ortin J., Lopez-Galindez C., Perez-Brena P., Villanueva N., Najera R. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: Biological relevance - A review. Gene. 40:1985;1-8.
8. Duarte E. A., Novella I. S., Weaver S. C., Domingo E., Wain-Hobson S., Clarke D. K., Moya A., Elena S. F., de la Torre J. C., Holland J. J. RNA virus quasispecies: Significance for viral disease and epidemiology. Infect. Agents Dis. 3:1994;201-214.
9. Kawamura N., Kohara M., Abe S., Komatsu T., Tago K., Arita M., Nomoto A. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63:1989;1302-1309.
10. Lu Z., Douthitt M. P., Taffs R. E., Ran Y., Norwood L. P., Chumakov K. M. Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC). PCR Methods Appl. 3:1993;176-180.
11. Lu Z., Rezapkin G. V., Douthitt M. P., Ran Y., Asher D. M., Levenbook I. S., Chumakov K. M. Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys. J. Gen. Virol. 77:1996;273-280.
12. McGoldrick A., Macadam A. J., Dunn G., Rowe A., Burlison J., Minor P. D., Meredith J., Evans D. J., Almond J. W. Role of mutations G-480 and C-6203 in the attenuation phenotype of sabin type-1 poliovirus. J. Virol. 69:1995;7601-7605.
13. Pilipenko E. V., Poperechny K. V., Maslova S. V., Melchers W. J., Slot H. J., Agol V. I. Cis-element, oriR, involved in the initiation of (-) strand poliovirus RNA: A quasi-globular multi-domain RNA structure maintained by tertiary ('kissing') interactions. EMBO J. 15:1996;5428-5436.
14. Rezapkin G. V., Chumakov K. M., Lu Z., Ran Y., Dragunsky E. M., Levenbook I. S. Microevolution of Sabin 1 strainin vitro. Virology. 202:1994;370-378.
15. Sabin A. B. Characteristics and genetic potentialities of experimentally produced and naturally occurring variants of poliomyelitis virus. Ann. N.Y. Acad. Sci. 61:1955;924-938.
16. Sabin A. B. Properties and behavior of orally administered attenuated poliovirus vaccine. J. Am. Med. Assoc. 164:1957;1216-1223.
17. Sabin A. B. Reproductive capacity of polioviruses of diverseorigin at various temperatures. Perspectives in Virology. 1961;Burgess Publishing, Minneapolis. p. 90-108.
18. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor. p. 16.41-16.46.
19. Strebel P. M., Sutter R. W., Cochi S. L., Biellik R. J., Brink E. W., Kew O. M., Pallansch M. A., Orenstein W. A., Hinman A. R. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14:1992;568-579.
20. Toyoda H., Kohara M., Kataoka Y., Suganuma T., Omata T., Imura N., Nomoto A. Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J. Mol. Biol. 174:1984;561-585.
21. Ward C. D., Flanegan J. B. Determination of the poliovirus RNA polymerase error frequency at eight sites in the viral genome. J. Virol. 66:1992;3784-3793.
22. Westrop G. D., Wareham K. A., Evans D. M., Dunn G., Minor P. D., Magrath D. I., Taffs F., Marsden S., Skinner M. A., Schild G. C.et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63:1989;1338-1344.
23. WHO, 1990, Requirements for poliovirus vaccine (oral), In, WHO Technical Reports, 800, 30, 65, World Health Organization, Geneva.